Navigation Links
5-Year Follow-Up Outpatient of L4-L5 Fixation with Inspan Device for Degenerative Spinal Stenosis Demonstrates Improved Results
Date:2/11/2020

INSPAN LLC (a privately-owned company) is pleased to announce the successful results from a long-term follow-up clinical study of outpatient L4-L5 lumbar interspinous fixation for degenerative spinal stenosis using the Inspan interspinous fixation device (INSPAN LLC). Unlike extension block design, the Inspan device fixates the spine to allow for immediate stability, distraction, decompression, and fusion. Based on biomechanical studies, the Inspan device may be the strongest interspinous fixation device on the market and thus is being used for spinal fusion replacing the traditional method that uses pedicle screws and interbodies with laminectomies

The study was performed at the LESS Institute by Professor Dr. Kingsley R Chin, MD, a board-certified orthopedic spine surgeon and coauthors Dr. Fabio Pencle and Dr. Jason Seale.

The study was a retrospective review of prospectively collected data under an IRB approved study cohort. The study evaluated 122 surgical cases of lumbar decompression with interspinous fixation from September 2011 to October 2016. A total of 56 patients had instrumentation at L4-L5. Total female population was 46%. The median age of the patients included in the population was 50.9+/-10.7 years with a median BMI of 24.8+/-11.4 kg/m2. Two-year VAS and ODI showed significant improvement form 8.1+/-1.2 to 1.5+/-1.1 and 42.9+/-14.3 to 14.8+/-5.1. All surgeries were completed in less than one hour. There was a total of one revision case with removal of Inspan and converted to an open hemilaminectomy decompression.

In conclusion, the long-term outcome of the study demonstrated improved outcomes in patients who underwent interspinous distraction decompression in an ambulatory surgery center using the Inspan device at L4-L5 for degenerative spinal stenosis. There were no complications or implant failures.

About INSPAN, LLC
INSPAN, LLC is privately owned by KICVentures and is focused on advancing the platform of patented interspinous fixation technology. The Inspan device has a proven ten-year track record with thousands implanted since FDA-clearance in 2010.

Inspan FDA Indications
The Inspan Slim Spinous Process Plate System is a posterior non-pedicle supplemental fixation system intended for use in the non-cervical spine (T1-S1). It is intended for plate fixation/attachment to the spinous process for the purpose of achieving supplemental fusion for the following indications: spondylolisthesis, trauma (fracture ordislocation), tumor, or degenerative disc disease (defined as discogenic pain with degeneration of the disc confirmed by history and radiographic studies). The device is intended for use with bone graft material and is not intended for stand-alone use.

Read the full story at https://www.prweb.com/releases/5_year_follow_up_outpatient_of_l4_l5_fixation_with_inspan_device_for_degenerative_spinal_stenosis_demonstrates_improved_results/prweb16896859.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. AxioMed Announces 15-year Exclusive Worldwide License on Proprietary Viscoelastic Material with the patent holder DSM
2. Organogenesis Awarded a 5-Year Federal Supply Schedule Agreement with the Department of Veteran Affairs
3. Alexandria Real Estate Equities, Inc. Executes 15-Year Lease Extension with NIH for 60,000 RSF of Mission-Critical Space at Alexandrias 9800 Medical Center Drive Campus in Shady Grove Life Sciences Center
4. AxioMed Accomplishes Significant Milestone: Two-Year USA IDE Clinical Study Follow-Up Completed for Viscoelastic Lumbar Disc
5. Soligenix Announces Positive Long-Term Follow-up Results from its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
6. Positive New, Long-Term Follow-Up Data of Asterias Biotherapeutics AST-VAC1 Cancer Vaccine Demonstrates Prolonged Relapse-Free Survival in Patients with High-Risk Acute Myelogenous Leukemia (AML)
7. Celladon Corporation Announces Oral Presentation at American Heart Association of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
8. Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
9. Follow-up Tests Confirm Success of Enviro-Equipment Inc.’s Powdered Activated Carbon (PAC) CleanInject® Remediation System
10. AxioMed Energized by Publication Showing Success of Outpatient Cervical Disc Replacements
11. Newly Published Spine Surgery Study Shows Cervical Total Disc Replacement To Provide Better Results Than Fusion in Outpatient Setting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2020)... ... 01, 2020 , ... Slone Partners , a nationwide ... placement of Julianne Averill , CPA, as Chief Financial Officer at ... implementing key business strategies to accelerate Alveo’s growth as the company advances its ...
(Date:8/15/2020)... ... 13, 2020 , ... Inc. magazine today revealed that Skysis ... of the nation’s fastest-growing private companies. The list represents a unique look at ... businesses. Intuit, Zappos, Under Armour, Microsoft, Patagonia, and many other well-known names gained ...
(Date:8/12/2020)... (PRWEB) , ... August 12, 2020 , ... ... Inc. (EMMA International), a global leader in FDA compliance consulting has been ... nation’s fastest-growing private companies. The list represents a unique look at the most ...
(Date:8/3/2020)... Ky. (PRWEB) , ... August 03, 2020 , ... Introducing ... products for transformative growth, , Known as MediVet Biologics since ... brand. , The new Ardent Animal Health will build on its base ...
Breaking Biology Technology:
(Date:7/10/2020)... ... July 09, 2020 , ... Today CJ BIO announced the first in a ... the “fifth taste” phenomenon that is revolutionizing ingredient mixes, nutritional content and flavor profiles ... on Monday, July 13, 2020 at11:00 AM (CDT) during SHIFT20, the virtual edition of ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. ... Neihulizumab, a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at ... Paul J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label ...
(Date:7/1/2020)... ... July 01, 2020 , ... Catalent, a global leader in ... Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of Japan. , ... Kakegawa, the new 60,000-square-foot facility will provide customers with flexible clinical supply solutions, ...
Breaking Biology News(10 mins):